Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in QNRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 212K | $1.4M | 0.0% | 10.786% | 0.15% |
| 2 | Dauntless Investment Group, LLC | 197K | $1.3M | β | 10.024% | 3.46% |
| 3 | SummitTX Capital, L.P. | 100K | $662K | +54.8% | 5.114% | 0.02% |
| 4 | Velan Capital Investment Management LP | 85K | $560K | β | 4.326% | 0.35% |
| 5 | Woodline Partners LP | 80K | $525K | 0.0% | 4.058% | 0.00% |
| 6 | MILLENNIUM MANAGEMENT LLC | 76K | $503K | +1.9% | 3.888% | 0.00% |
| 7 | abrdn plc | 75K | $495K | 0.0% | 3.824% | 0.00% |
| 8 | Soleus Capital Management, L.P. | 73K | $480K | +190.9% | 3.708% | 0.02% |
| 9 | Centiva Capital, LP | 60K | $396K | +397.8% | 3.059% | 0.00% |
| 10 | BOOTHBAY FUND MANAGEMENT, LLC | 60K | $395K | 0.0% | 3.051% | 0.01% |
| 11 | Stonepine Capital Management, LLC | 53K | $353K | -31.6% | 2.726% | 0.28% |
| 12 | AIGH Capital Management LLC | 51K | $337K | +3.4% | 2.600% | 0.07% |
| 13 | CITADEL ADVISORS LLC | 33K | $215K | β | 1.658% | 0.00% |
| 14 | Birchview Capital, LP | 20K | $132K | β | 1.020% | 0.08% |
| 15 | MORGAN STANLEY | 4K | $26K | +33.3% | 0.204% | 0.00% |
| 16 | UBS Group AG | 3K | $17K | +14676.5% | 0.128% | 0.00% |
| 17 | GAMMA Investing LLC | 2K | $11K | -17.5% | 0.088% | 0.00% |
| 18 | RHUMBLINE ADVISERS | 2K | $10K | -8.7% | 0.078% | 0.00% |
| 19 | BARCLAYS PLC | 1K | $9K | β | 0.066% | 0.00% |
| 20 | SBI Securities Co., Ltd. | 2 | $13 | -99.2% | 0.000% | 0.00% |
| 21 | ROYAL BANK OF CANADA | 11 | $0 | β | 0.001% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in QNRX β a direct measure of their conviction.
Filings activity in QNRX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new QNRX position in Q1 2026
Institutions that fully closed their QNRX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 21 | +17% | 94.93% | 52.72 pp | $8M | 36% |
| Q4 2025 | 18 | +350% | 147.65% | +147.52 pp | $12M | +113394% |
| Q3 2025 | 4 | 43% | 0.13% | 0.15 pp | $0M | 54% |
| Q2 2025 | 7 | 36% | 0.28% | 0.82 pp | $0M | 74% |
| Q1 2025 | 11 | 27% | 1.10% | 10.90 pp | $0M | 91% |
| Q4 2024 | 15 | +88% | 12.00% | +11.16 pp | $1M | +1327% |
| Q3 2024 | 8 | 27% | 0.84% | 0.71 pp | $0M | 46% |
| Q2 2024 | 11 | β | 1.55% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying QNRX stock.
Based on Q1 2026 13F filings, institutional ownership of Quoin Pharmaceuticals, Ltd. stands at 94.9%, held across 21 reporting institutions.
Ikarian Capital, LLC is the largest reported institutional holder of QNRX, with approximately 211,538 shares worth $0.00B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of QNRX, including MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for QNRX is 50 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
6 institutions opened new positions in QNRX during Q1 2026, while 3 fully exited. 3 added to existing positions and 12 trimmed.
QNRX institutional ownership fell by 52.72 percentage points quarter-over-quarter, with a net change of +3 holders.
The top 10 institutions account for 85.8% of all reported 13F value in QNRX, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Quoin Pharmaceuticals, Ltd. (QNRX) Institutional Ownership